{"entity":{"type":"insider","cik":"0001910662","url":"/insider/0001910662","json_url":"/insider/0001910662.json","name":"LaBrosse Nicole","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":6,"first":"2022-11-16","last":"2025-09-23","span_basis":"filed_date"},"name_variants":[{"name":"LaBrosse Nicole","source":"filing","n_filings":6,"first_seen":"2022-11-16","last_seen":"2025-09-23"}],"transactions":[{"id":5101199,"accession":"0001910662-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001910662-25-000003","line_url":"/filing/0001910662-25-000003","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2227.0,"shares_display":"2,227","price_per_share":77.94543735967669,"price_display":"77.95","price_state":"stated","total_value":173584.489,"total_display":"173,584.49","total_whole":"173,584","shares_owned_after":22393.0,"shares_owned_after_display":"22,393","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-22","filed_date":"2025-09-23","scope":"insider","n_lines":2},{"id":5125851,"accession":"0001415889-25-024295","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-024295","line_url":"/filing/0001415889-25-024295","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":75.713356,"price_display":"75.71","price_state":"stated","total_value":1514267.12,"total_display":"1,514,267.12","total_whole":"1,514,267","shares_owned_after":24306.0,"shares_owned_after_display":"24,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-10","filed_date":"2025-09-11","scope":"insider","n_lines":2},{"id":2330504,"accession":"0001415889-24-019936","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-019936","line_url":"/filing/0001415889-24-019936","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":53.93236,"price_display":"53.93","price_state":"stated","total_value":269661.8,"total_display":"269,661.80","total_whole":"269,662","shares_owned_after":15480.0,"shares_owned_after_display":"15,480","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-23","scope":"insider","n_lines":2},{"id":2132115,"accession":"0001415889-24-018408","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-018408","line_url":"/filing/0001415889-24-018408#line-6","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":52.04,"price_display":"52.04","price_state":"stated","total_value":520400.0,"total_display":"520,400.00","total_whole":"520,400","shares_owned_after":15480.0,"shares_owned_after_display":"15,480","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-28","filed_date":"2024-06-28","scope":"insider"},{"id":2132105,"accession":"0001415889-24-018408","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-018408","line_url":"/filing/0001415889-24-018408#line-4","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":51.934,"price_display":"51.93","price_state":"stated","total_value":519340.0,"total_display":"519,340.00","total_whole":"519,340","shares_owned_after":15480.0,"shares_owned_after_display":"15,480","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-27","filed_date":"2024-06-28","scope":"insider"},{"id":2132099,"accession":"0001415889-24-018408","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-018408","line_url":"/filing/0001415889-24-018408#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":51.82,"price_display":"51.82","price_state":"stated","total_value":518200.0,"total_display":"518,200.00","total_whole":"518,200","shares_owned_after":15480.0,"shares_owned_after_display":"15,480","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-26","filed_date":"2024-06-28","scope":"insider"},{"id":8516088,"accession":"0001415889-23-002954","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-002954","line_url":"/filing/0001415889-23-002954#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2525.0,"shares_display":"2,525","price_per_share":49.26,"price_display":"49.26","price_state":"stated","total_value":124381.5,"total_display":"124,381.50","total_whole":"124,382","shares_owned_after":9066.0,"shares_owned_after_display":"9,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-16","filed_date":"2023-02-21","scope":"insider"},{"id":6569798,"accession":"0001415889-22-011459","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-22-011459","line_url":"/filing/0001415889-22-011459","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001910662","owner_name":"LaBrosse Nicole","owner_display_name":"LaBrosse Nicole","owner_url":"/insider/0001910662","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":53.81051,"price_display":"53.81","price_state":"stated","total_value":269052.55,"total_display":"269,052.55","total_whole":"269,053","shares_owned_after":4410.0,"shares_owned_after_display":"4,410","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-16","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001159036","name":"HALOZYME THERAPEUTICS, INC.","url":"/issuer/0001159036","role":"Officer (SVP, CHIEF FINANCIAL OFFICER)","n_filings":6,"first_seen":"2022-11-16","last_seen":"2025-09-23"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001910662","retrieved_at":"2026-08-23T20:22:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}